Dr Reddy's buys rights to 2 HRT drug brands from UK’s Mercury Pharma for $32-M

Hyderabad-based, publicly listed Dr. Reddy’s Laboratories has acquired the trademarks for the specialty brands Progynova and Cyclo-Progynova, along with related assets for the Indian market, from UK-headquartered Mercury Pharma Group valuing the transaction at USD 32.15 million.Progynova (estradiol valerate) is an oral hormone replacement therapy (HRT) indicated for the treatment of estrogen deficiency symptoms and the prevention of post-menopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined HRT for estrogen deficiency symptoms, providing both estrogen and progestogen components.This acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks its strategic entry into the HRT segment. The company intends to leverage its established market access to expand the reach of the acquired assets.